Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?

Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?

Cancer and the Combination Approach

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

Jazz Pharmaceuticals Celebrates International Women’s Day

20 States with the Cheapest Weed in America

Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month

Unlocking Jazz Pharmaceuticals' Potential: A Roadmap for Growth

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Jazz Pharmaceuticals (NASDAQ:JAZZ) shareholders have endured a 32% loss from investing in the stock three years ago